Telix Pharmaceuticals Limited - American Depositary Shares (TLX)
TLX moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How TLX actually reacts to news — the realized, point-in-time move the market made, measured across 1,060 labeled events over the last three years with zero look-ahead.
TLX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 969 |
| 30-min | 0.00% | 49% | 1,039 |
| 60-min | 0.00% | 50% | 1,042 |
| to close | 0.00% | 50% | 1,034 |
| Middle 50% of TLX reactions | -0.55% to +0.54% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 1,060 |
Half of all Telix Pharmaceuticals Limited - American Depositary Shares news events land between -0.55% and +0.54% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How TLX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 16 | -1.21% | 19% | -1.66% |
| Rating reiterations | 39 | +0.47% | 51% | +0.74% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how TLX ranks against every other measured name →
That’s how TLX usually reacts — get an email when it moves on news →Email me when TLX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TLX's baseline. Nothing else.
Recent TLX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Telix Reports Third Quarter 2026 Financial Performance | Press release | GlobeNewswire | — | — | |
| Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S. | Press release | GlobeNewswire | +0.56% | +0.28% | |
| Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM | Press release | PR Newswire | -0.37% | -0.56% | |
| Telix to Host Capital Markets Day in Melbourne on November 4, 2026 | Press release | PR Newswire | -0.09% | +0.90% | |
| First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18) | Press release | GlobeNewswire | -0.73% | -1.64% | |
| Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging | Press release | PR Newswire | -1.16% | -2.31% | |
| Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse | Press release | GlobeNewswire | -1.06% | +0.09% | |
| FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara | Press release | GlobeNewswire | -1.19% | -3.44% | |
| FDA Approves Telix's Brain Cancer Imaging Drug Pixclara | Press release | PR Newswire | -1.19% | -3.44% | |
| Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.66% | +2.15% | |
| Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway | Press release | GlobeNewswire | +1.32% | +0.44% | |
| Telix Appoints David Gill as Chair | Press release | GlobeNewswire | -0.18% | -0.82% | |
| Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline | Press release | PR Newswire | +0.33% | +1.30% | |
| Telix to Host R&D Day in New York City on September 22, 2026 | Press release | GlobeNewswire | -0.10% | -0.38% | |
| Telix H1 2026 Results: Investor Webcast Notification | Press release | GlobeNewswire | -0.20% | -1.10% | |
| TLX591-Tx ProstACT SELECT Study Published in Cancers Journal | Press release | GlobeNewswire | +0.10% | -1.62% | |
| Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer | Press release | GlobeNewswire | +1.13% | +3.12% | |
| Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress | Press release | PR Newswire | +1.13% | +3.12% | |
| Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study | Press release | PR Newswire | -1.15% | +0.29% | |
| First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer | Press release | GlobeNewswire | -1.28% | -1.00% | |
| Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing | Press release | PR Newswire | -1.28% | -1.00% | |
| FDA Alignment to Advance ProstACT Global Phase 3 Trial | Press release | GlobeNewswire | +0.33% | -1.82% | |
| Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions | Press release | PR Newswire | +0.90% | +1.69% | |
| Telix and United Imaging Announce Strategic Theranostics Collaboration | Press release | GlobeNewswire | +0.54% | -0.43% | |
| ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 | Press release | GlobeNewswire | +0.54% | -0.43% | |
| Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences | Press release | GlobeNewswire | +0.41% | +0.31% | |
| Form 6-K Telix Pharmaceuticals For: May 20 | SEC filing · Form 6-K | SEC EDGAR | -1.03% | -1.97% | |
| IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing | Press release | GlobeNewswire | +0.10% | +0.00% | |
| Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches | Press release | GlobeNewswire | -3.18% | -1.12% | |
| New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC | Press release | GlobeNewswire | -0.49% | -0.99% | |
| TLX101-Px (Pixlumi®) MAA Accepted in Europe | Press release | GlobeNewswire | +0.91% | +1.90% | |
| OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer | Press release | GlobeNewswire | +0.81% | +4.46% | |
| Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next-Generation Portfolio Approach | Press release | GlobeNewswire | +0.00% | -0.29% | |
| Form 6-K Telix Pharmaceuticals For: Apr 22 | SEC filing · Form 6-K | SEC EDGAR | +0.05% | -1.55% | |
| Form 6-K Telix Pharmaceuticals For: Apr 20 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.19% | |
| ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026 | Press release | GlobeNewswire | +0.00% | +0.19% | |
| Form 6-K Telix Pharmaceuticals For: Apr 19 | SEC filing · Form 6-K | SEC EDGAR | -1.43% | -2.57% | |
| Form 6-K Telix Pharmaceuticals For: Apr 14 | SEC filing · Form 6-K | SEC EDGAR | +2.98% | -0.47% | |
| Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma | Press release | PR Newswire | -0.84% | +0.09% | |
| Telix Refinances Convertible Bonds | Press release | PR Newswire | +2.98% | -0.47% | |
| Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds | Press release | PR Newswire | -0.84% | +0.09% | |
| Form 6-K Telix Pharmaceuticals For: Apr 12 | SEC filing · Form 6-K | SEC EDGAR | +2.98% | -0.47% | |
| Telix and Regeneron Announce Strategic Radiopharma Collaboration | Press release | GlobeNewswire | -0.09% | +1.90% | |
| Form 6-K Telix Pharmaceuticals For: Apr 09 | SEC filing · Form 6-K | SEC EDGAR | +4.95% | +4.36% | |
| FDA Accepts NDA for TLX101-Px (Pixclara®) | Press release | GlobeNewswire | +4.95% | +4.36% | |
| Form 6-K Telix Pharmaceuticals For: Apr 09 | SEC filing · Form 6-K | SEC EDGAR | -1.01% | +0.20% | |
| Telix Strengthens Board with Additional Director Appointments | Press release | GlobeNewswire | -1.01% | +0.20% | |
| Form 6-K Telix Pharmaceuticals For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | — | +0.79% | |
| Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement | Press release | GlobeNewswire | -0.10% | +1.48% | |
| Form 6-K Telix Pharmaceuticals For: Apr 01 | SEC filing · Form 6-K | SEC EDGAR | -0.43% | -1.20% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TLX section they belong to.
Where else TLX is measured.
TLX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Telix Pharmaceuticals Limited - American Depositary Shares's median reaction calculated?
Every labeled TLX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,060 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of TLX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TLX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.